

<p>Informazione Regolamentata n. 0957-37-2023</p>	<p>Data/Ora Inizio Diffusione 03 Luglio 2023 13:05:40</p>	<p>Euronext Milan</p>
---	---	-----------------------

Societa' : DIASORIN

Identificativo : 178912

Informazione  
Regolamentata

Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio  
Giovanni Vaccarone

Tipologia : 2.2

Data/Ora Ricezione : 03 Luglio 2023 13:05:32

Data/Ora Inizio  
Diffusione : 03 Luglio 2023 13:05:40

Oggetto : Suspension of the effectiveness of the  
disqualifying accessory administrative  
sanction imposed by CONSOB to the Chief  
Executive Officer Mr. Carlo Rosa

*Testo del comunicato*

See attachment.

## **SUSPENSION OF THE EFFECTIVENESS OF THE DISQUALIFYING ACCESSORY ADMINISTRATIVE SANCTION IMPOSED BY CONSOB TO THE CHIEF EXECUTIVE OFFICER MR. CARLO ROSA.**

**Saluggia, July 3, 2023** – DiaSorin informs that the Court of Appeal of Milan suspended the effectiveness of the disqualifying administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa, for the alleged unlawful disclosure of inside information regarding the completion of the studies for the launch of the serological test for the diagnosis and identification of the immune response to SARS-CoV-2.

Mr. Rosa is immediately reinstated in the administration, management and control offices held in the Company.

The above decision was granted in the legal proceedings promoted by Mr. Rosa in order to obtain the complete annulment of the decision adopted by CONSOB.

### **About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 41 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasoringroup.com](http://www.diasoringroup.com)

### **For additional information, please contact:**

**Riccardo Fava**  
*Corporate Vice President Communication & Investor Relations*  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Eugenia Ragazzo**  
*Corporate Investor Relations & ESG Analyst*  
[eugenia.ragazzo@diasorin.it](mailto:eugenia.ragazzo@diasorin.it)

Fine Comunicato n.0957-37

Numero di Pagine: 3